Results 141 to 150 of about 5,906,643 (291)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Strengthening laboratory management towards accreditation in Tanzania: The 13 years of remarkable revolutions in laboratory quality management system. [PDF]

PLoS One
Torokaa PR, Massambu C, Lusekelo J, Julius R, Magesa AS, Majigo M, Joachim A, Kelly ME, Kyalo A, Moremi N.   +9 more
europepmc   +1 more source

Radiological transportation risk assessment of the shipment of sodium-bonded fuel from the Fast Flux Test Facility to the Idaho National Engineering Laboratory

, 1995
J.R. Green
openalex   +2 more sources

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Enrollment Problems and Training Models for Training Postgraduate Students in Clinical Laboratory Diagnosis (Professional Degree) During the "Four Certificates in One" Era in China. [PDF]

Adv Med Educ Pract
Yan Z, Fu Y, Cui Y, Kuang L, Shi H, Liu T, Liu X, Jiang Y.   +7 more
europepmc   +1 more source

Laboratory

American Journal of Public Health and the Nations Health, 1934
openaire   +3 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Representation and Utilization of Laboratory Data in CT-Based Acute Abdominal Emergency Radiology: A Methodological Content Analysis. [PDF]

Tomography
Tiryaki Baştuğ B, Güney T.
europepmc   +1 more source

Properties and Units in the Clinical Laboratory Sciences VI. Properties and Units in Ioc Prohibited Drugs

, 2016
H. L. Olesen, D. Cowan, Ivan Bruunshuus, K. Klempel, Gordon Hill   +4 more
openalex   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source